RLMD - Relmada Corp Market Capitalization-to-Revenue Ratio
The normalized P/S of Relmada Therapeutics (RLMD) reflects the business valuation trend, with the parameter reaching . Relmada Therapeutics integrates ESG principles by adhering to bioethical testing standards and laboratory environmental sustainability. Patent protection for its unique antidepressants enables premium pricing power. Vast market potential and the completion of clinical stages guarantee high future demand for this innovative therapy.
Metric breakdowns and analytics for Relmada (RLMD)
- stock value and consensus price forecast:
- market capitalization statistics:
- book capitalization indicators:
- business debt structure and liquidity details:
- earnings and market ratios statistics:
RLMD - Net Income|Projected Future Earnings Relmada Therapeutics|RLMD - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Relmada Therapeutics Inc|RLMD - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Relmada|RLMD - Operating profit EBITDA|Net earnings per share for the last 12 months Relmada Therapeutics|RLMD - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months relmada.com|RLMD - Earnings per share growth in current year|Expected earnings per share trend next year Relmada Therapeutics
- issuer revenue and sales details:
General company analysis:RLMD relmada.com
The valuation of Relmada Therapeutics (RLMD) depends directly on the outcomes of the REL-1017 trials and the drug's safety profile. The historical P/S ratio illustrates the market capitalization relative to current sales volumes. The current value of reflects the proportion between the share price and revenue, measuring the degree of premium paid for future success. Sharp fluctuations in this ratio signal shifting investor expectations regarding the product's commercialization.
Competitors of Relmada Therapeutics
P/S Multiple biogen.com (BIIB)|Neurocrine Biosciences, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RGC|AXSM: Market Cap to Revenue|ACADIA Corp - Market Cap to Sales Volume|XENE: P/S Multiple|vikingtherapeutics.com - Market Capitalization-to-Revenue Ratio|SUPN (Supernus) - P/S Multiple|Price to Sales Catalyst Pharma CPRX|Price-to-Revenue Ratio Denali Therapeutics Inc (DNLI)|HRMY (Harmony Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple BHVN (Biohaven Ltd.)|P/S Multiple amylyx.com AMLX|TRVI - Price-to-Revenue Ratio|Price-to-Sales Ratio PRAX|AVXL: P/S Multiple|Price to Sales CeriBell EEG (CBLL)|Market Cap to Revenue PRTA|P/S Multiple Alector Therapeutics|Market Cap to Revenue ANNX (Annexon)|Market Cap to Sales Volume OMER|P/S Multiple NGNE (Neurogene Corp)|Price-to-Revenue Coefficient AC Immune Inc (ACIU)|Voyager Therapeutics - P/S Multiple|neumoratx.com (NMRA) - Market Cap to Revenue|Scilex (SCLX) - Price-to-Revenue Ratio|TVGN - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Alpha Cognition Inc|CGTX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Inhibikase Therapeutics (IKT)|Price-to-Revenue Ratio SAVA (cassavasciences.com)|Price-to-Revenue Ratio Assertio ASRT|COYA - Market Cap to Revenue|VistaGen Therapeutics Inc - P/S Multiple|OVID (Ovid Therapeutics Inc.) - Market Cap to Revenue Ratio|Acumen Pharmaceuticals (ABOS) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CRVO|ATHE (Alterity Therapeutics Ltd.) - P/S Multiple|Price to Sales Clene Nanomedicine CLNN|Market Cap to Revenue PEPG (PepGen Inc.)|P/S Multiple Jupiter Neurosciences, Inc. (JUNS)|Price-to-Revenue Ratio Annovis Bio, Inc. ANVS|Market Capitalization-to-Revenue Ratio GRCE|AIFF - Price-to-Revenue Ratio|Price to Sales Klotho Neurosciences Inc|neurosense-tx.com (NRSN) - Price-to-Revenue Ratio|Reviva Pharmaceuticals, Inc. - Market Capitalization-to-Revenue Ratio|MTVA (MetaVia Inc.) - P/S Multiple|Price to Sales neuraxis.com NRXS|Price-to-Revenue Ratio Helius Medical (HSDT)|Price-to-Revenue Ratio PASG (passagebio.com)|Price-to-Revenue Ratio Neuphoria Therapeutics NEUP|NERV - Market Cap to Revenue|Athira Pharma, Inc. - P/S Multiple|ADXN - P/S Multiple|ALZN: P/S Multiple|Market Cap to Revenue Ratio CYCN|PTIX (Protagenic Therapeutics Inc.) - P/S Multiple|P/S Multiple Pasithea|Market Cap to Revenue CRGT (Cortigent, Inc.)|ATXI (avenuetx.com) - Market Capitalization-to-Revenue Ratio|BrainStorm Cell Therapeutics - Market Cap to Revenue|Market Cap to Sales Volume CARA (Cara Therapeutics Inc.)|Chromocell Therapeutics Corporation - P/S Multiple|Market Capitalization-to-Revenue Ratio ELYM (Eliem Therapeutics)|ITCI: P/S Multiple|Price to Sales longboardpharma.com (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|P/S Multiple NRBO|P/S Multiple Sage Therapeutics Inc (SAGE)|Price-to-Revenue Ratio Synaptogenix, Inc. SNPX|TRVN (trevena.com) - Price-to-Sales Ratio|Vigil Neuro - P/S Multiple|Price to Sales anewmeds.com|CERE (Cerevel) - Market Cap to Revenue
